Profile data is unavailable for this security.
About the company
Shanghai Allist Pharmaceuticals Co Ltd is a China-based company focusing on the field of tumor treatment. The Company has built a research and development pipeline in the field of small molecule targeted drugs for non-small cell lung cancer. The Company has established a complete new drug research and development system, covering all aspects of lead drug discovery and optimization, candidate drug evaluation and establishment, drug preclinical and clinical research, drug registration and application, industrialization and commercialization. The Company has a number of research pipeline projects under development, such as vometinib. Its drugs are used in the fields of blood pressure reduction, anti-tumor, anti-diabetic and gastric acid related diseases.
- Revenue in CNY (TTM)3.20bn
- Net income in CNY1.30bn
- Incorporated2004
- Employees1.04k
- LocationShanghai Allist Pharmaceuticals Co LtdNo. 268 Lingxiaohua RoadZhoupu Town, Pudong New AreaSHANGHAI 201318ChinaCHN
- Phone+86 2 180423292
- Fax+86 2 180423291
- Websitehttps://www.allist.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| InnoCare Pharma Ltd | 898.92m | -375.51m | 12.95bn | 1.09k | -- | 3.52 | -- | 14.41 | -0.2325 | -0.2325 | 0.537 | 3.86 | 0.0922 | 1.32 | 3.73 | 825,457.90 | -4.02 | -- | -4.78 | -- | 84.50 | -- | -43.57 | -- | 7.65 | -- | 0.1547 | -- | 18.09 | -- | 28.80 | -- | -- | -- |
| Joinn Laboratories China Co Ltd | 2.12bn | -912.86k | 13.00bn | 2.59k | -- | 1.77 | -- | 6.12 | -0.0064 | -0.0064 | 2.82 | 10.68 | 0.2151 | 0.7714 | 7.32 | -- | -0.09 | 8.99 | -0.106 | 11.07 | 31.83 | 46.76 | -0.4184 | 32.01 | 2.85 | 1.25 | 0.0089 | 23.81 | 4.78 | 42.20 | -63.04 | 29.66 | 8.21 | 23.46 |
| RemeGen Co Ltd | 1.52bn | -1.55bn | 15.72bn | 3.62k | -- | 8.11 | -- | 10.32 | -2.88 | -2.88 | 2.83 | 4.35 | 0.2712 | 0.4446 | 5.00 | 421,122.40 | -27.65 | -18.66 | -36.21 | -23.69 | 78.65 | 81.64 | -101.95 | -102.21 | 0.9558 | -32.19 | 0.5167 | -- | 40.26 | 141.16 | -51.30 | -- | 59.07 | -- |
| Sinocelltech Group Ltd | 2.45bn | -24.64m | 17.98bn | 2.33k | -- | -- | -- | 7.35 | -0.0553 | -0.0553 | 5.49 | -0.2874 | 0.8146 | 0.4624 | 5.26 | 1,048,041.00 | -0.8674 | -40.17 | -2.70 | -74.63 | 95.83 | 95.42 | -1.06 | -108.20 | 0.588 | 5.45 | 1.05 | -- | 84.46 | 264.19 | 23.70 | -- | 37.54 | -- |
| Dizal Pharmaceutical Co Ltd | 389.64m | -837.22m | 19.39bn | 581.00 | -- | 45.27 | -- | 49.78 | -2.04 | -2.04 | 0.9471 | 1.03 | 0.235 | 0.4033 | 6.15 | 670,632.10 | -56.00 | -46.02 | -83.89 | -52.99 | 97.17 | 57.53 | -238.28 | -2,081.54 | 1.66 | -193.39 | 0.674 | -- | -- | 18.29 | -50.50 | -- | 21.35 | -- |
| Shanghai Allist Pharmaceuticals Co Ltd | 3.20bn | 1.30bn | 25.37bn | 1.04k | 19.56 | 5.22 | -- | 7.92 | 2.88 | 2.88 | 7.12 | 10.81 | 0.6811 | 3.60 | 11.38 | 3,068,832.00 | 27.57 | 0.6405 | 30.38 | 0.6933 | 94.43 | 96.42 | 40.47 | 2.54 | 6.89 | -- | 0.0003 | 211.88 | 155.14 | 237.34 | 393.54 | -- | 13.53 | -- |
Data as of Sep 13 2024. Currency figures normalised to Shanghai Allist Pharmaceuticals Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
10.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Aegon-Industrial Fund Management Co., Ltd.as of 30 Sep 2023 | 4.20m | 2.03% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 4.09m | 1.98% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 2.62m | 1.27% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2024 | 2.57m | 1.24% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 2.55m | 1.23% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 1.55m | 0.75% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 1.12m | 0.54% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 1.12m | 0.54% |
| Ping An Fund Management Co., Ltd.as of 30 Jun 2024 | 1.00m | 0.49% |
| Bank of China Investment Management Co., Ltd.as of 30 Jun 2024 | 909.96k | 0.44% |
More ▼
Data from 30 Jun 2024 - 11 Nov 2024Source: FactSet Research Systems Inc.
